AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Beam Therapeutics 2025 Q1 Earnings Misses Targets with Net Income Decline of 10.7%
Generated by AI AgentAinvest Earnings Report Digest
Wednesday, May 7, 2025 8:34 am ET2min read
Beam Therapeutics (BEAM) reported its fiscal 2025 Q1 earnings on May 06th, 2025. The company missed expectations as its net income declined 10.7% compared to the previous year. Despite the financial challenges, continues to make significant progress in its clinical programs. The company maintained its guidance, expecting to continue dose-escalation trials for BEAM-302 and BEAM-301, and to present updated data in the second half of 2025. Beam's strong cash position, reinforced by recent financing, supports its projected cash runway into 2028.
Revenue
Beam Therapeutics reported a slight increase in total revenue for Q1 2025, amounting to $7.47 million, compared to $7.41 million in Q1 2024. This growth was primarily driven by license and collaboration revenue, which also totaled $7.47 million.
Earnings/Net Income
Beam Therapeutics experienced a wider loss per share in Q1 2025, with losses deepening to $1.24 per share, compared to $1.21 per share in Q1 2024. The company's net loss increased to $109.27 million, representing a 10.7% rise from the previous year. The EPS results indicate ongoing financial challenges.
Price Action
The stock price of has plummeted 17.15% during the latest trading day, has plummeted 18.87% during the most recent full trading week, and has edged down 2.86% month-to-date.
Post-Earnings Price Action Review
Over the past five years, the strategy of purchasing Beam Therapeutics shares following a quarter-over-quarter revenue drop and holding for 30 days has delivered a 54.49% return, which falls short of the benchmark return of 83.12%. This strategy resulted in an excess return of -28.63% and achieved a compound annual growth rate of 9.20%. Despite the strategy's performance, it exhibits volatility at 16.91% and a maximum drawdown of -12.47%, alongside a Sharpe ratio of 0.54. These figures highlight the potential risks involved in employing this investment approach, though it has been moderately effective in terms of return.
CEO Commentary
Beam Therapeutics has had a tremendous start to what we anticipate will be a transformative year. In March, we achieved a historic milestone with BEAM-302, delivering the first-ever clinical genetic correction of a disease-causing mutation for alpha-1 antitrypsin deficiency. Building on this momentum, we have swiftly advanced the program—initiating the fourth cohort of Part A of the Phase 1/2 BEAM-302 study and securing U.S. FDA clearance for our investigational new drug application, positioning us for continued rapid progress. Additionally, we recently dosed the first patient in our second in vivo program, BEAM-301, a potential treatment for glycogen storage disease type Ia. This significant clinical progress is supported by our strong financial foundation, further reinforced by our recent $500 million financing, which extends our projected cash runway into 2028.
Guidance
Beam plans to continue the dose-escalation portion of Part A of the ongoing BEAM-302 Phase 1/2 clinical trial and expects to report further data at a medical conference in the second half of 2025. The company anticipates dosing the first patient in Part B of the BEAM-302 trial, which will include AATD patients with mild to moderate liver disease, in the second half of 2025. Additionally, Beam expects to dose 30 patients in the BEACON Phase 1/2 clinical trial of BEAM-101 in adults with severe SCD by mid-2025 and plans to present updated data during EHA 2025 in June.
Additional News
Recent developments at Beam Therapeutics include the dosing of the first patient in the U.S.-based Phase 1/2 clinical trial for BEAM-301, aimed at treating glycogen storage disease type Ia. This program represents Beam's second clinical-stage in vivo editing initiative. The company also announced that updated data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease have been accepted for presentation at the European Hematology Association Congress in June. Additionally, Beam Therapeutics received clearance from the U.S. FDA for its investigational new drug application for BEAM-302, following positive initial data in treating alpha-1 antitrypsin deficiency.
Revenue
Beam Therapeutics reported a slight increase in total revenue for Q1 2025, amounting to $7.47 million, compared to $7.41 million in Q1 2024. This growth was primarily driven by license and collaboration revenue, which also totaled $7.47 million.
Earnings/Net Income
Beam Therapeutics experienced a wider loss per share in Q1 2025, with losses deepening to $1.24 per share, compared to $1.21 per share in Q1 2024. The company's net loss increased to $109.27 million, representing a 10.7% rise from the previous year. The EPS results indicate ongoing financial challenges.
Price Action
The stock price of has plummeted 17.15% during the latest trading day, has plummeted 18.87% during the most recent full trading week, and has edged down 2.86% month-to-date.
Post-Earnings Price Action Review
Over the past five years, the strategy of purchasing Beam Therapeutics shares following a quarter-over-quarter revenue drop and holding for 30 days has delivered a 54.49% return, which falls short of the benchmark return of 83.12%. This strategy resulted in an excess return of -28.63% and achieved a compound annual growth rate of 9.20%. Despite the strategy's performance, it exhibits volatility at 16.91% and a maximum drawdown of -12.47%, alongside a Sharpe ratio of 0.54. These figures highlight the potential risks involved in employing this investment approach, though it has been moderately effective in terms of return.
CEO Commentary
Beam Therapeutics has had a tremendous start to what we anticipate will be a transformative year. In March, we achieved a historic milestone with BEAM-302, delivering the first-ever clinical genetic correction of a disease-causing mutation for alpha-1 antitrypsin deficiency. Building on this momentum, we have swiftly advanced the program—initiating the fourth cohort of Part A of the Phase 1/2 BEAM-302 study and securing U.S. FDA clearance for our investigational new drug application, positioning us for continued rapid progress. Additionally, we recently dosed the first patient in our second in vivo program, BEAM-301, a potential treatment for glycogen storage disease type Ia. This significant clinical progress is supported by our strong financial foundation, further reinforced by our recent $500 million financing, which extends our projected cash runway into 2028.
Guidance
Beam plans to continue the dose-escalation portion of Part A of the ongoing BEAM-302 Phase 1/2 clinical trial and expects to report further data at a medical conference in the second half of 2025. The company anticipates dosing the first patient in Part B of the BEAM-302 trial, which will include AATD patients with mild to moderate liver disease, in the second half of 2025. Additionally, Beam expects to dose 30 patients in the BEACON Phase 1/2 clinical trial of BEAM-101 in adults with severe SCD by mid-2025 and plans to present updated data during EHA 2025 in June.
Additional News
Recent developments at Beam Therapeutics include the dosing of the first patient in the U.S.-based Phase 1/2 clinical trial for BEAM-301, aimed at treating glycogen storage disease type Ia. This program represents Beam's second clinical-stage in vivo editing initiative. The company also announced that updated data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease have been accepted for presentation at the European Hematology Association Congress in June. Additionally, Beam Therapeutics received clearance from the U.S. FDA for its investigational new drug application for BEAM-302, following positive initial data in treating alpha-1 antitrypsin deficiency.
Ainvest Earnings Report Digest
Get noticed about the list of notable companies` earning reports after markets close today and before markets open tomorrow.
Latest Articles
Electrovaya 2025 Q4 Earnings Record Net Income Surges 1896.5% from Loss
Dec.20 2025
Winnebago Industries 2026 Q1 Earnings Record Revenue and 205.8% Net Income Turnaround
Dec.19 2025
Paychex 2026 Q2 Earnings Beats Revenue Estimates, EPS Falls Short
Dec.19 2025
Lamb Weston Holdings 2026 Q2 Earnings 272% Net Income Surge and 1.1% Revenue Growth
Dec.19 2025
ConAgra Brands 2026 Q2 Earnings Sharp Net Loss Amid Revenue Decline and EPS Drop
Dec.19 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet